Bristol Myers Squibb to acquire Forbius
Forbius’s lead TGF-beta asset, AVID200, is an isoform-selective TGF-beta inhibitor, currently in Phase 1 for oncology and fibrosis
Recover your password.
A password will be e-mailed to you.